BioMarin Pharmaceutical Inc. (BMRN) exhibits 77.7% gross margins and 6.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 21.0x enterprise multiple and 6.7% implied options volatility.
Sustained 77.7% gross profitability converts into 12.7% operating margin and 6.0% ROIC, outpacing sector cost of capital.
ROIC: 6.0% // GM: 77.7%YoY revenue trajectory of +12.9% paired with 6.51% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +12.9% // FCF YLD: 6.51%Altman Z-Score of 5.57 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 5.57 // F-SCORE: 8/9Trading at 31.9x trailing P/E (26.8x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 31.9x // EV/EBITDA: 21.0xOptions market prices a ±6.7% implied move with a 0.67 put/call ratio around $56.00 max pain.
IMPL MOVE: ±6.7% // P/C: 0.67Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 10.8% net margins.
NET MARGIN: 10.8% // D/E: 0.10x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for BMRN & activate live FRED threshold breach alerts.